Saturday, May 25, 2019

The U.S. Food and Drug Administration on Friday approved Incyte Corp's treatment for acute Graft versus Host disease (GvHD), an inflammatory response by the immune system after a bone marrow transplant.


from Reuters: Health News https://reut.rs/2YFQp4e

Related Posts:

  • LATEST HEALTH NEWSA federal judge ruled on Monday against birth control organizations that sought to block the Trump administration from shifting a federal family-planning grant program toward prioritizing groups that are faith-based and couns… Read More
  • LATEST HEALTH NEWSRoche said on Tuesday its investigational drug baloxavir marboxil reduced symptoms in people at high risk of complications from flu, a boost to the Swiss drugmaker's efforts to win approval for the single-dose, oral anti-vira… Read More
  • LATEST HEALTH NEWSA court hearing on a Texas law requiring the burial or cremation of aborted fetal tissue opened on Monday with the state arguing the requirement was a matter of dignity, while abortion providers called it unnecessary and aime… Read More
  • LATEST HEALTH NEWSSwiss drugmaker Roche's hopes of recapturing lost ground in the generics-flooded influenza market got a boost after a late-stage study showed its new medicine reduced symptoms in people at high risk of complications. fro… Read More
  • LATEST HEALTH NEWSAbbVie Inc said on Tuesday it signed a U.S. licensing deal with Mylan NV for its proposed biosimilar to AbbVie's blockbuster drug Humira, in a move that will give it more near-term control over the competition. from Reut… Read More

0 comments:

Post a Comment

Followers

Contact Form

Name

Email *

Message *

Popular Posts

FOLLOW BY EMAIL

Enter your email address:

Delivered by FeedBurner